

Anjali Tiku Owens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7022645/publications.pdf>

Version: 2024-02-01

46
papers

1,441
citations

471509

17
h-index

361022

35
g-index

47
all docs

47
docs citations

47
times ranked

2454
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020, 11, 163.	12.8	466
2	Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. <i>Circulation</i> , 2019, 140, 31-41.	1.6	195
3	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	2.8	90
4	Reversal of Pacing-Induced Cardiomyopathy Following Cardiac Resynchronization Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 168-177.	3.2	70
5	Pathogenic LMNA variants disrupt cardiac lamina-chromatin interactions and de-repress alternative fate genes. <i>Cell Stem Cell</i> , 2021, 28, 938-954.e9.	11.1	61
6	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1818-1824.	30.7	51
7	Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. <i>Circulation</i> , 2021, 144, 1646-1655.	1.6	51
8	Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 3932-3944.	2.2	43
9	A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes. <i>Genetics in Medicine</i> , 2020, 22, 102-111.	2.4	42
10	Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, 458-485.	3.6	39
11	New Management Strategies in Heart Failure. <i>Circulation Research</i> , 2016, 118, 480-495.	4.5	37
12	Coronavirus disease 2019 in heart transplant recipients: Risk factors, immunosuppression, and outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 926-935.	0.6	36
13	Functional Annotation of TNNT2 Variants of Uncertain Significance With Genome-Edited Cardiomyocytes. <i>Circulation</i> , 2018, 138, 2852-2854.	1.6	32
14	Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank Participants. <i>Circulation</i> , 2022, 146, 110-124.	1.6	25
15	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. <i>Circulation: Heart Failure</i> , 2021, 14, e007957.	3.9	24
16	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	6.1	22
17	The Year in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 60, 359-368.	2.8	19
18	Neprilysin Inhibitors: Emerging Therapy for Heart Failure. <i>Annual Review of Medicine</i> , 2017, 68, 41-49.	12.2	16

#	ARTICLE	IF	CITATIONS
19	Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant Alone. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	13
20	<i>ACTA1</i> Novel Likely Pathogenic Variant in a Family With Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002243.	3.6	12
21	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
22	Baseline Characteristics of the VANISH Cohort. <i>Circulation: Heart Failure</i> , 2019, 12, e006231.	3.9	10
23	From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies. <i>Current Heart Failure Reports</i> , 2019, 16, 157-167.	3.3	9
24	Advances in the Genetics and Genomics of Heart Failure. <i>Current Cardiology Reports</i> , 2020, 22, 132.	2.9	9
25	Should Left Ventricular Assist Device Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?. <i>Circulation</i> , 2012, 126, 3088-3094.	1.6	7
26	Ventricular Septal Defect from Takotsubo Syndrome. <i>Case Reports in Cardiology</i> , 2016, 2016, 1-4.	0.2	6
27	Cardiovascular Characteristics of Patients with Genetic Variation in Desmoplakin (DSP). <i>Neurology International</i> , 2022, 12, 24-36.	0.5	6
28	Clinical and procedural characteristics predicting need for chronotropic support and permanent pacing post-heart transplantation. <i>Heart Rhythm</i> , 2020, 17, 1132-1138.	0.7	5
29	Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. <i>Cardiology and Therapy</i> , 2022, 11, 249-267.	2.6	5
30	Pregnancy in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2017, 38, 2691-2692.	2.2	4
31	Cardioprotection in Duchenne muscular dystrophy. <i>European Heart Journal</i> , 2021, 42, 1985-1987.	2.2	4
32	Reappraising Genes for Dilated Cardiomyopathy: Stepping Back to Move Forward. <i>Circulation</i> , 2021, 144, 20-22.	1.6	4
33	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	1.7	4
34	Pulmonary hypertension: Barrier or just a bump in the road in transplanting adults with congenital heart disease. <i>Congenital Heart Disease</i> , 2018, 13, 492-498.	0.2	2
35	Decoding Dysfunction in Duchenne Muscular Dystrophy Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002051.	3.6	2
36	Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: An interview study. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2021, 50, 788-793.	1.6	2

#	ARTICLE	IF	CITATIONS
37	End Stage Mitochondrial Cardiomyopathy and Heart Transplantation Due to Biallelic Pathogenic <i>C1QB</i> Variants. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, CIRCGEN121003559.	3.6	2
38	A Parallel Need for Cardiovascular Care for Female Carriers of Duchenne and Becker Muscular Dystrophy. <i>Journal of Cardiac Failure</i> , 2022, 28, 1235-1236.	1.7	2
39	Recreational Exercise in Hypertrophic Cardiomyopathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1319.	7.4	1
40	Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients. <i>American Heart Journal</i> , 2021, 240, 11-15.	2.7	1
41	Cardiovascular Genetics. <i>Medical Clinics of North America</i> , 2022, 106, 313-324.	2.5	1
42	Good Intentions Gone Bad. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002560.	3.6	0
43	Antepartum Diagnosis and Management of Lamin A/C Disease. <i>Case Reports in Cardiology</i> , 2019, 2019, 1-6.	0.2	0
44	Clinical utility of surveillance and clinically prompted right heart catheterization in patients listed for heart transplantation. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 28-34.	1.7	0
45	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e10.	3.0	0
46	Left Ventricular Hypertrophy and Hypertrophic Cardiomyopathy in Adult Solid Organ Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1279.	1.6	0